Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 15 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has received final approval from the USFDA for Eltrombopag Tablets in various strengths. These tablets are used to treat low platelet counts in specific blood disorders by stimulating platelet production. The tablets will be manufactured at Zydus's facility in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 15, 2026, titled "Zydus receives final approval from USFDA for Eltrombopag Tablets,12.5 mg, 25 mg, 50 mg, and 75 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases